NCT06991114RecruitingPhase 2
An Open-label Phase 2a Study to Evaluate the Safety and Efficacy of AlloNK®, an Allogeneic Cord Blood-derived NK Cell Therapy, in Combination With Rituximab in Relapsing Forms of B-cell Dependent Rheumatologic Diseases
Artiva Biotherapeutics, Inc.63 sites in 3 countries90 target enrollmentStarted: July 9, 2025Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Artiva Biotherapeutics, Inc.
- Enrollment
- 90
- Locations
- 63
- Primary Endpoint
- Safety
Study Overview
Brief Summary
A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically modified allogeneic NK cell, in combination with rituximab.
Detailed Description
An open-label Phase 2a study to evaluate the safety and efficacy of AlloNK®, an allogeneic cord blood-derived NK cell therapy, in combination with rituximab in relapsing forms of B-cell dependent rheumatologic diseases.
AlloNK® (also known as AB-101) is a non-genetically modified, allogeneic, off-the-shelf, cryopreserved cord blood-derived NK cell therapy.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •For Subjects with Refractory Rheumatoid Arthritis (RA):
- •Documented diagnosis of RA, meeting the 2010 ACR/EULAR classification criteria.
- •Rheumatoid Factor (RF) or Anti Citrullinated Protein Antibody (ACPA) positive.
- •High-sensitivity C-reactive protein (hs-CRP) > 3 mg/L or Erythrocyte Sedimentation Rate (ESR) > 28 mm/hr.
- •Have had prior treatment for a period of at least 12 weeks with a biologic disease modifying anti-rheumatic drug and were deemed refractory by the treating physician.
- •Minimum of six swollen joint counts (SJC) and six tender joint counts (TJC) according to joint assessment.
- •For subjects with Sjögren's Disease (SjD)
- •Prior diagnosis of Primary SjD as per 2016 ACR/EULAR criteria with confirmatory diagnosis in the 24 weeks preceding screening.
- •Total Clinical European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (clinESSDAI) >
- •Salivary Flow Rate > 0.1 mL/min on stimulation.
- •For subjects with Idiopathic Inflammatory Myopathies (IIMs)
- •Presence of a positive autoantibody (ANA >1:80 or RNP or SSA/SSB or other myositis specific autoantibodies.
- •Refractory IIM as defined by inadequate response/intolerance to at least 3 months of glucocorticoids and/or at least one other immunosuppressive.
- •Muscle biopsy or muscle MRI to confirm IIM diagnosis, where applicable, within 12 months prior to enrollment.
- •For Subjects with Systemic Sclerosis (SSc)
- •Diagnosis of SSc in accordance with the ACR/EULAR 2013 classification.
- •Modified Rodnan skin score (mRSS) >
- •Initial confirmatory diagnosis within 8 years of screening.
- •Refractory SSc as defined by inadequate response/intolerance to at least 3 months of glucocorticoids and/or at least one other immunosuppressive.
Exclusion Criteria
- Not provided
Arms & Interventions
AlloNK
Experimental
AlloNK, dosed after a conditioning regimen, combined with Rituximab.
Intervention: Allogeneic NK Cells (Drug)
Outcomes
Primary Outcomes
Safety
Time Frame: From enrollment until the end of treatment at Week 104.
Dose Limiting toxicities assessed in a incrementing dose design.
Secondary Outcomes
- Rheumatoid Arthritis: Disease Activity Score 28 (DAS28 - ESR)(Week 52)
- Sjögren's Disease: Improvement in Clinical EULAR Sjögren's Syndrome Disease Activity Index (ClinESSDAI)(Week 52)
- Idiopathic Inflammatory Myopathies: Total Improvement Score (TIS)(Week 52)
- Systemic Sclerosis: Revised Composite Response Index in Systemic Sclerosis (rCRISS)(Week 52)
Investigators
Study Sites (63)
Loading locations...
Similar Trials
Terminated
Phase 1
Safety and Efficacy of Adipose Derived Stem Cells in Refractory Rheumatoid Arthritis, Systemic Lupus Erythematosus or Sharp's SyndromeSharp's SyndromeRheumatoid ArthritisSystemic Lupus ErythematosusNCT02741362Arkansas Heart Hospital2
Unknown
Phase 4
Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar GelRheumatoid ArthritisNCT03082573Iraj Sabahi Research Inc.30
Active, not recruiting
Phase 1
Study to Assess the Safety and Efficacy of Enbrel Administered by Sofusa DoseConnect for Rheumatoid ArthritisRheumatoid ArthritisNCT04559412Sorrento Therapeutics, Inc.11
Completed
Phase 2
Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With AdalimumabRheumatoid ArthritisNCT01752855AbbVie (prior sponsor, Abbott)88
Completed
Not Applicable
A Study of Tocilizumab in Patients With Rheumatoid ArthritisRheumatoid ArthritisNCT01187563Regeneron Pharmaceuticals16